Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID‐19) infected patients

Suxin Wan(Chongqing University), Qingjie Yi(Chongqing University), Shibing Fan(Chongqing University), Jinglong Lv(Chongqing University), Xianxiang Zhang(Chongqing University), Lian Guo(Chongqing University), Chunhui Lang(Chongqing University), Qing Xiao(The Affiliated Yongchuan Hospital of Chongqing Medical University), Kaihu Xiao(Chongqing University), Zhengjun Yi(Chongqing University), Qiang Mao(Qingdao University), Jianglin Xiang(Chongqing University), Bangshuo Zhang(Chongqing University), Yongping Chen(Chongqing University), Cailiang Gao(Chongqing University)
British Journal of Haematology
April 16, 2020
Cited by 327Open Access
Full Text

Abstract

Summary We explored the relationships between lymphocyte subsets, cytokines, pulmonary inflammation index (PII) and disease evolution in patients with (corona virus disease 2019) COVID‐19. A total of 123 patients with COVID‐19 were divided into mild and severe groups. Lymphocyte subsets and cytokines were detected on the first day of hospital admission and lung computed tomography results were quantified by PII. Difference analysis and correlation analysis were performed on the two groups. A total of 102 mild and 21 severe patients were included in the analysis. There were significant differences in cluster of differentiation 4 (CD4 + T), cluster of differentiation 8 (CD8 + T), interleukin 6 (IL‐6), interleukin 10 (IL‐10) and PII between the two groups. There were significant positive correlations between CD4 + T and CD8 + T, IL‐6 and IL‐10 in the mild group ( r 2 = 0·694, r 2 = 0·633, respectively; P < 0·01). After ‘five‐in‐one’ treatment, all patients were discharged with the exception of the four who died. Higher survival rates occurred in the mild group and in those with IL‐6 within normal values. CD4 + T, CD8 + T, IL‐6, IL‐10 and PII can be used as indicators of disease evolution, and the PII can be used as an independent indicator for disease progression of COVID‐19.


Related Papers

No related papers found

Powered by citation graph analysis